anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Method for separating cells in a centrifuge, preferably for producing platelets. A cell suspension is provided in a processing bag and is centrifuged. The cell enriched fraction is transferred to a storage bag via an outlet tube. The outlet tube is arranged with a portion thereof in a position adjacent the periphery of said centrifuge. When the enriched fraction is transferred through the outlet tube placed at said periphery of the centrifuge and during centrifugation, the outlet tube operates as a cell trap and the enriched fraction is further separated. Preferably, the cell suspension is buffy coat and the enriched fraction comprises platelets. The corresponding bag assembly comprises a processing bag (1) intended to enclose the cell suspension. The processing bag is placed in a centrifuge rotor (10) for separating the cells into a fraction enriched on platelets by centrifugation. An outlet tube (3) transfers the enriched fraction to a storage bag and is placed in a position adjacent the periphery of the centrifuge rotor for further separation of said enriched fraction at transferring, during continued centrifugation, said enriched fraction through the outlet tube (3).
Right after general anesthesia induction and patient intubation, the patient will be placed in the semi-sitting position with the arm in extension and abduction. Following sterile skin preparation, a SHAC block will be performed by the same anaesthesiologist under ultrasound guidance by visualization of the interfascial space between the deep lamina of the deltoid muscle fascia and the superficial lamina of the subscapularis fascia and glenohumeral pericapsular space. A 22-gauge 50-mm insulated stimulating needle (StimuPlex Nanoline, Braun) will be used to give 1-3 mL of 5% Dextrose for the correct location and then 15 mL local anesthetic solution will be divided into 7,5 mL (0.375 % bupivacaine 5 mL and 2 % lidocaine 2,5 mL) for each target points as interfascial space and pericapsular space.
Subjects will receive stereotactic body radiotherapy (SBRT) within 4 weeks of enrollment. Following SBRT, subjects will receive one cycle of pre-operative pembrolizumab given as an IV over approximately 30 minutes. Surgical management to remove all known sites of metastatic disease should occur 2 weeks post pembrolizumab treatment. Approximately 4-8 weeks after surgery subjects will being the second phase of pembrolizumab treatment. They will receive this treatment every 3 weeks (cycle) for 8 more cycles after surgery. Prior to the 5th cycle of pembrolizumab subjects will also have tumor imaging (CT or MRI).
The present invention provides a use of Desmodium caudatum extract for preparing a composition for treating breast cancer. Specifically, by administering a composition containing an effective dose of Desmodium caudatum extract to a breast cancer patient, it can effectively inhibit the growth of breast cancer cells, thereby achieving the effect of treating breast cancer or delaying the progression of breast cancer. The composition is a pharmaceutical composition or a food product. More preferably, the pharmaceutical composition contains an effective dose of Desmodium caudatum extract and a pharmaceutically acceptable carrier and/or excipient. The food product contains Desmodium caudatum extract and an acceptable carrier in food manufacturing, wherein the food product can be nutritional supplements, drinks, or cookies. The Desmodium caudatum extract contains polyphenol compound and flavonoid compound. The Desmodium caudatum extract is obtained by preparing Desmodium caudatum, using water as an extraction solvent to extract at high temperature, and drying the filtrate. The concentration of Desmodium caudatum extract is at least 100 μg/mL. Preferably, the concentration of Desmodium caudatum extract is 250~500 μg/mL. The Desmodium caudatum extract can inhibit the performance of at least one protein selected from a group consisting of cyclinD1, cyclinE, E2F, cdk2, cdk4, p-Rb/Rb and Bcl-2. The Desmodium caudatum extract can enhance the performance of at least one protein selected from a group consisting of cleaved-casepase 3 and CAD. Thus, the Desmodium caudatum extract for preparing a composition for treating breast cancer according to the present invention can be used as an adjunctive therapy for clinical treatment of breast cancer to improve the prognosis of breast cancer and reduce the recurrence rate. In addition, the Desmodium caudatum extract can inhibit the proliferation of breast cancer without causing serious side effects to the organism so that it can be used as an active ingredient of pharmaceutical composition or adjuvant.
A suppository comprises a core containing an active ingredient mixed with an inert base and coated with a substance which contains no active ingredient but serves as a lubricant when the suppository is inserted in the body.  The active ingredient or ingredients e.g. oxycodone pectinate, morphine pectinate, theophylline or a mixture of hydrocortisone acetate, benzocaine and bismuth subgallate, are mixed and moist granulated with an inert base e.g. maize starch, lactose, polyvinyl pyrrolidone, kaolin levis or mixtures thereof.  The mixture is shaped and compressed to form a core.  The coating comprising hydrogenated fat, a mixture of polyethylene glycols in alcohol, cocoa butter or a polyvinyl pyrrolidone is applied to the core in a coating pan. The disintegration time of the core is controlled by adjusting the composition or the compactness of the inert base.
Our previous study has demonstrated that sulfated Chinese yam polysaccharide (SCYP) can improve immunomodulatory activity in Raw 264.7 cells. However, its anti-inflammatory is little known. In this study, the anti-inflammatory effects of SCYP were systematically investigated via the Lipopolysaccharides (LPS)-induced Raw264.7 cell model, Caco-2/Raw264.7 co-culture system, and acute inflammation mice model. The results suggested SCYP promoted the cell proliferation and have no toxicity in Raw264.7 and Caco-2 cells at the concentration of 200 µg/mL. Moreover, when treated with SCYP, the production of pro-inflammatory cytokines (interleukin [IL]-1β, IL-6, and tumor necrosis factor-α) reduced significantly in Raw264.7 via the MAPK/NF-κB pathway. In the Caco-2/Raw264.7 co-cultured system, SCYP could regulate inflammation reaction by improving intestinal barrier, which might prevent systemic inflammation. Further, systemic inflammation was alleviated by SCYP in LPS-induced acute inflammation mice through MAPK/NF-κB pathway. PRACTICAL APPLICATION: These results supported that SCYP may be used as an anti-inflammation agent in the functional food field.
The present invention relates to a film-coating table for treating gastrointestinal diseases, and to a method for producing the same. Ranitidine, bismuth, and sucralfate are uniformly mixed and contained as active components in a single layer. The sucralfate is formed in a granule form along with a binder. The tablet includes a damp-proof coating layer including polyvinyl alcohol. Provided is an improved production process capable of improving stability and productivity of a gastrointestinal disease treating pharmaceutical composition including ranitidine hydrochloride, sucralfate, and potassium bismuth citrate. According to the present invention, while sucralfate is formed in a wet granule, a table can be produced by mixing ranitidine hydrochloride and potassium bismuth citrate. Accordingly, production can be simply performed, and a phase stability degradation problem caused by conventionality of ranitidine hydrochloride is resolved. At the same time, a single layer table is produced, and thus economic feasibility can be improved. Moreover, a produced tablet provides consumption convenience by having a small size, and ensures high quality uniformity by having a low ranitidine elusion deviation between products.
Chlordiazepoxide Hydrochloride and Clidinium Bromide combines in a single capsule formulation the antianxiety action of chlordiazepoxide hydrochloride and the anticholinergic/spasmolytic effects of clidinium bromide.

Each Chlordiazepoxide Hydrochloride and Clidinium Bromide capsule contains the active ingredients 5 mg chlordiazepoxide hydrochloride and 2.5 mg clidinium bromide.

Each capsule also contains the inactive ingredients lactose monohydrate, pregelatinized starch, talc. Gelatin capsule shells may contain titanium dioxide with the following dye systems: D&C Yellow #10, FD&C Green #3 and gelatin.

Chlordiazepoxide hydrochloride is a versatile, therapeutic agent of proven value for the relief of anxiety and tension. It is indicated when anxiety, tension or apprehension are significant components of the clinical profile. It is among the safer of the effective psychopharmacologic compounds.

Chlordiazepoxide hydrochloride is 7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine 4-oxide hydrochloride. A colorless, crystalline substance, it is soluble in water. It is unstable in solution and the powder must be protected from light. The molecular weight is 336.22. The structural formula of chlordiazepoxide hydrochloride is as follows:

Clidinium bromide is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. Structurally clidinium bromide is:
The widely used chemotherapeutic drug doxorubicin (DOX) has been associated with adverse effects on the skeletal muscle, which can persist for years after the end of the treatment. These adverse effects may be exacerbated in older patients, whose skeletal muscle might already be impaired by aging. Nonetheless, the mediators responsible for DOX-induced myotoxicity are still largely unidentified, particularly the ones involved in the long-term effects that negatively affect the quality of life of the patients. Therefore, this study aimed to investigate the long-term effects of the chronic administration of DOX on the soleus muscle of aged mice. For that and to mimic the clinical regimen, a dose of 1.5 mg kg-1 of DOX was administered two times per week for three consecutive weeks in a cumulative dose of 9 mg kg-1 to 19-month-old male mice, which were sacrificed two months after the last administration. Body wasting and the atrophy of the soleus muscle, as measured by a decrease in the cross-sectional area of the soleus muscle fibers, were identified as long-term effects of DOX administration. The atrophy observed was correlated with increased reactive oxygen species production and caspase-3 activity. An impaired skeletal muscle regeneration was also suggested due to the correlation between satellite cells activation and the soleus muscle fibers atrophy. Systemic inflammation, skeletal muscle energy metabolism and neuromuscular junction-related markers do not appear to be involved in the long-term DOX-induced skeletal muscle atrophy. The data provided by this study shed light on the mediators involved in the overlooked long-term DOX-induced myotoxicity, paving the way to the improvement of the quality of life and survival rates of older cancer patients.
BACKGROUND: About 70% of women affected by ovarian cancer experience relapse within 2 years of diagnosis. Traditionally, the standard treatment for recurrent ovarian cancer (ROC) has been represented by systemic chemotherapy.1 Recently, several retrospective studies have suggested that secondary cytoreductive surgery could provide better clinical outcomes than chemotherapy alone, in the case of complete tumor cytoreduction.2,3 About 50% of patients with ROC have a pelvic component of the disease and 22% of patients present isolated pelvic recurrence, often involving the rectum.4,5 Minimally invasive secondary cytoreductive surgery is a feasible option and is associated with favorable perioperative outcomes.6-8 It is crucial to fully explore the peritoneal cavity before starting cytoreductive procedures in order to confirm the absence of carcinomatosis.9 The robotic system facilitates the identification of anatomical structures and makes it easier to perform complex surgical steps in narrow spaces. It also allows the integrated use of surgical tools such as intraoperative ultrasound and indocyanine green application.
METHODS: In this video, we present the case of a 64-year-old woman who experienced a rectal recurrence of ovarian cancer after a platinum-free interval of 12 months. We describe, in a step-by-step manner, the surgical procedure of a robotic rectosigmoid resection with totally intracorporeal colorectal anastomosis (TICA).10-12 RESULTS: Robotic secondary cytoreduction with complete gross resection was achieved. The patient did not report any intraoperative or postoperative complications. Final histology confirmed ROC.
CONCLUSION: Totally robotic rectosigmoid resection is a feasible option in isolated bowel recurrences. Thanks to continuous technical evolution, robot-assisted surgery has the potential to have a central role in the fight against solid tumors. Integration of multiple pre- and intraoperative technologies allows personalized surgery to be performed for each different patient.13,14.
PROBLEM TO BE SOLVED: To obtain a cosmetic capable of hiding shape trouble of skin such as wrinkles, skin pores or roughness of texture and improving color tone trouble such as dermal stains or ephelides, excellent in persistence of effects and finishing the skin natural by including a silicon nitride having specific average particle diameter and a platy powder. SOLUTION: This cosmetic is obtained by including (A) a silicon nitride having 0.01-2 μm average particle diameter and (B) a platy powder (e.g. mucovite or biotite). The ingredients A and B preferably form a composite powder containing the ingredient A present on the surface of the ingredient B. The weight ratio of the ingredient A based on the sum total of the ingredients A and B is preferably 0.01-0.8. The average thickness of the ingredient B is <=1 μm. The average particle diameter thereof is preferably 10-60 μm. The formulation amount of the sum total of the ingredients A and B formulated in the cosmetic is 2-90 wt.%. A powder such as silicic acid, silicic acid anhydride, magnesium silicate or kaolin can be used in the cosmetic.
The present invention addresses the problem of providing a compound or a pharmacologically acceptable salt thereof, said compound being to be used for promoting osteogenesis, improving bone metabolism, preventing or treating bone fracture and preventing or treating diseases relating to bone metabolism, or for promoting healing in bone diseases such as bone fracture, bone defect or osteoarthritis in the field of plastic surgery and treating periodontal disease or stabilizing artificial tooth roots in the field of dentistry. Provided is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The meanings of the substituents in formula (I) are as follows: R 1  represents a halogen atom, etc.; R 2  represents a hydrogen atom, etc.; R 3  represents a hydrogen atom, etc.; R 4  represents a hydrogen atom, etc.; and A represents a heterocyclic group, etc.
The goal of this study is to identify the most efficacious pressure of administration and the minimum number of rubbing cycles necessary to perforate the stratum corneum (the outermost layer of the skin).

Many medical indications are treated through the topical application of a therapeutic compound formulated into a gel, cream, ointment, or lotion (e.g., eczema, psoriasis, actinic keratosis, cutaneous warts, etc.). This is especially true in dermatology in which the skin is often the primary site of action. Topicals (i.e., drugs applied to the skin's surface) allow patients to easily self-apply these therapies without the need for painful or difficult-to-use medical technologies (e.g., hypodermic needles) or the risks associated with systemic exposure to a drug (e.g., oral, intravenous, or intramuscular administration).

Despite the advantages associated with topical delivery, the skin serves as a barrier in the transport of most external compounds. There are several techniques to overcome the skin barrier. There have been several studies to increase skin permeability such as chemical, biochemical, and physical methods. However, chemical and biochemical methods do not appear to be broadly useful for the delivery of large molecule therapeutics (e.g., peptides, proteins, genetic material) across the skin. STAR particles are millimeter-scale particles with micron-scale projections made of biocompatible materials that painlessly disrupt the stratum corneum. As STAR particles are rubbed on the skin, their microscopic projections create micron-scale pores in the stratum corneum to increase skin permeability to topical compounds independent of physicochemical properties. After the arms of the STAR particle puncture the skin, the elastic forces of the skin push the particles out. The first 10 participants will receive the 8 interventions (different application pressures) plus the control (Site and treatment will not be randomly assigned on the arm) by the investigator. In addition, two applications of STAR particles will be applied to one of the hands. After these participants have completed the study, an interim analysis will be performed. At this point, a decision will be made by the investigator to determine if changes in STAR particle administration will be implemented for the next 10 participants.
The invention discloses traditional Chinese medicine for treating carotid plaque and belongs to the technical field of Chinese herbal medicine preparations. The traditional Chinese medicine is prepared from, by mass, 3 g of panax notoginseng powder, 15 g of prepared radix polygoni multiflori, 20 g of radix puerariae, 15 g of fructus crataegi and 5 g of hirudo. The preparation method includes the steps that the panax notoginseng powder, prepared radix polygoni multiflori, radix puerariae, fructus crataegi and hirudo are prepared into particles and mixed, and the traditional Chinese medicine is prepared. Pure natural Chinese herbal medicine is particularly selected for the rigorous formula, the traditional Chinese medicine has the effects of nourishing the liver and the kidney, eliminating stasis and softening hard masses, accelerating elimination of carotid plaque and reducing the risk of stroke episode of a patient. The traditional Chinese medicine lowers morbidity, the death rate and the disability rate, relieves pain of the patient, improves living quality of the patient and is safe, free of toxin or side effects after being taken for a long time and more convenient to take after being decocted. The traditional Chinese medicine is low in cost and can relieve the economic burden of the patient and household.
BACKGROUND: Major surgery triggers trauma-like stress responses linked to age, surgery duration, and blood loss, resembling polytrauma. This similarity suggests elective surgery as a surrogate model for studying polytrauma immune responses. We investigated stress responses across age groups and compared them with those of polytrauma patients.
STUDY DESIGN: Patients undergoing major spinal reconstruction surgery were divided into older (age >65 years, n = 5) and young (age 18 to 39 years, n = 6) groups. A comparison group consisted of matched trauma patients (n = 8). Blood samples were collected before, during, and after surgery. Bone marrow mononuclear cells and peripheral blood mononuclear cells were analyzed using cellular indexing of transcriptomes and epitopes sequencing or single-cell RNA sequencing. Plasma was subjected to dual-platform proteomic analysis (SomaLogic and O-link).
RESULTS: Response to polytrauma was highest within 4 hours. By comparison, the response to surgery was highest at 24 hours. Both insults triggered significant changes in cluster of differentiation 14 monocytes, with increased inflammation and lower major histocompatibility complex-class 2 expression. Older patient's cluster of differentiation 14 monocytes displayed higher inflammation and less major histocompatibility complex-class 2 suppression; a trend was also seen in bone marrow mononuclear cells. Although natural killer cells were markedly activated after polytrauma, they were suppressed after surgery, especially in older patients. In plasma, innate immunity proteins dominated at 24 hours, shifting to adaptive immunity proteins by 6 weeks with heightened inflammation in older patients. Senescence-associated secretory phenotype proteins were higher in older patients at baseline and further elevated during and after surgery.
CONCLUSIONS: Although both major surgery and polytrauma initiate immune and stress responses, substantial differences exist in timing and cellular profiles, suggesting major elective surgery is not a suitable surrogate for the polytrauma response. Nonetheless, distinct responses in young vs older patients highlight the utility of elective spinal in studying patient-specific factors affecting outcomes after major elective surgery.
Cosmetic aerosol compos. comprises an active ingredient, CCl3F and a sufficient quantity of CO2 and/or NO2 to increase the pressure inside the aerosol container to 3 to 8, pref. 5 kg/cm2. The aerosol composn. can also contain =12% liquefied propellant gas such as CCl2F2. The active ingredient can be a resin for hair lacquers or a bactericide for deodorants. The use of CCl3F plus non-liqufiable gases such as CO2, NO2, instead of CCl2F2 ensures better solubility and dispersancy of the active ingredients and reduces the cost since expensive solvents are not required.
FIELD: medicine. SUBSTANCE: method involves applying emotional psychological tests, taking saliva samples, determining stress index based on hydrocortisone availability by means of photometer. Rehabilitation treatment course is selected on the basis of measurements undertaken on patients showing stress-like states. Music treatment, autotraining, odotherapy, rational psychotherapy is administered for rehabilitating the patients according to the present method. EFFECT: enhanced effectiveness in testing patient psychoemotional state; avoided undesirable complications caused by treatment. 1 tbl
The invention comprises compounds of the formula R-CO-S-CH(R1)-CO-NHR2, where R represents a lower alkyl or carboxyalkyl residue, and R1 and R2 each represent a hydrogen atom or a lower alkyl residue, "lower alkyl" meaning an alkyl group of 1 to 4 carbon atoms.  Examples describe the preparation of S - acetyl mercaptoacetamide, S - acetyl - N - methyl-mercaptoacetamide, S-acetyl-mercaptopropionamide and S - succinyl - mercaptoacetamide by reacting the appropriate mercaptoalkylamide with the appropriate acid anhydride or with acetyl chloride.  The novel compounds are useful in processes for the permanent waving of hair (see Group IV (c)).ALSO:A composition suitable for application to hair as a step in the permanent waving thereof comprises, in aqueous solution, a compound of the general formula: R-CO-S-CH(R1)-CO-NHR2, where R represents a lower alkyl or carboxyalkyl residue and R1 and R2 each represent a hydrogen atom or a lower alkyl residue, "lower alkyl" meaning an alkyl group of 1 to 4 carbon atoms, and a basic substance, such as ammonia or an ethanolamine, e.g. triethanolamine.  A process for the so-called permanent waving of hair comprises impregnating the hair, before or after constraining it into a desired configuration, with an aqueous solution of a mercapto compound of the above formula, and thereafter setting the hair in the desired configuration by a method known per se.  In one embodiment, the hair is impregnated with a non-alkaline aqueous solution of the mercapto compound, constrained into a desired configuration, impregnated with an aqueous alkaline solution and set in the desired configuration.
Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm\^2) of ChapStick Lip Moisturizer Black Cherry will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.